News

ARS Pharmaceuticals Secures Patent Validity for neffy® Spray

ARS Pharmaceuticals Secures Patent Validity for neffy® Spray

ARS Pharmaceuticals Achieves Key Patent Victory in Europe

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company based in San Diego, specializes in providing tools for at-risk individuals to effectively address allergic reactions that can culminate in anaphylaxis. Recently, the company received a positive ruling from the Opposition Division of the European Patent Office (EPO), which successfully upheld all claims of their patent EP 3678649. This patent is significant as it pertains to nasal spray epinephrine formulations that have been validated across over 30 countries in Europe, particularly utilizing alkyl-glycoside, like Intravail.

Strengthening the Patent Portfolio

ARS Pharma's global intellectual property assets related to the innovative product, neffy, offer robust coverage extending until at least 2039. This steadfastness in patent protection supports the company's competitive positioning in the market for emergency treatments against severe allergic reactions.

Similar Success in the United States

Earlier in the year, ARS Pharma successfully defended its patent rights in the United States. The United States Patent and Trademark Office (USPTO) upheld critical claims of U.S. Patent No. 10,682,414, which covers the method of treating type I hypersensitivity reactions, including anaphylaxis, using an epinephrine aqueous nasal spray. This dual success across different jurisdictions underscores the extensive validity of ARS's patents.

CEO Commentary

Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma, expressed his optimism regarding these favorable outcomes. He affirmed that "the decisive and unanimous opinion of the EPO committee in rejecting all opposition arguments affirms the strength and validity of our extensive patent portfolio." Lowenthal's comments highlight the company's confidence in successfully handling future patent challenges, especially those pertaining to intranasal epinephrine formulations.

About neffy®

Introduced as a groundbreaking tool for emergency management, neffy serves as an epinephrine nasal spray specifically designed for the urgent treatment of anaphylactic reactions in both adults and children aged four and above, who weigh at least 33 pounds. This innovative method provides an alternative form of administration compared to traditional injectable options.

Usage Instructions and Safety Information

The indication for neffy emphasizes that users should carry two nasal sprays at all times, as anaphylactic reactions can be unpredictable. If symptoms persist or worsen following the initial dose, a second spray may be necessary. neffy is intended only for intranasal use, and it is crucial to seek immediate medical assistance for additional treatment following any allergic reaction.

The Importance of Combatting Anaphylaxis

Anaphylaxis represents a severe and rapidly progressing allergic reaction typically necessitating immediate treatment with epinephrine, the only FDA-approved solution for such emergencies. Unfortunately, the current roster of epinephrine auto-injectors often presents challenges that deter prompt administration. Patient apprehensions, including needle phobia, complex operating procedures, and issues related to device reliability have resulted in a large number of individuals not using their prescribed devices in critical situations.

The Need for Effective Solutions

In the United States alone, around 40 million individuals are at risk for type I allergic reactions, underscoring a significant market potential for effective treatments like neffy. However, many patients face hurdles in carrying and using traditional epinephrine auto-injectors, although in recent years, a growing number have been diagnosed with severe allergies leading to anaphylaxis.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals aims to transform the landscape of allergic reaction treatments through neffy, which has been approved in the EU under the trade name EURneffy. This nasal spray is instrumental for immediate intervention for anaphylactic responses due to various allergic stimuli, making it a vital tool for both patients and caregivers.

Contact Information for ARS Pharmaceuticals

For inquiries, please contact ARS Pharmaceuticals at 1-877-MY-NEFFY (877-696-3339) or reach out to their media contacts. For further details about their innovative offerings, visit ARS Pharmaceuticals' official website.

Frequently Asked Questions

What is neffy®?

neffy® is a nasal spray built for the emergency treatment of allergic reactions, including anaphylaxis, for individuals weighing at least 33 pounds.

What recent patent news has ARS Pharmaceuticals announced?

ARS Pharmaceuticals has successfully upheld a patent related to neffy® at the European Patent Office, affirming the reliability of their product.

Why is epinephrine important in treating allergies?

Epinephrine is crucial as it rapidly counteracts severe allergic reactions, which can be life-threatening if not treated promptly.

What distinguishes neffy® from traditional epinephrine injectors?

neffy® provides a needle-free method for epinephrine administration, addressing fears associated with needles and simplifying the treatment process.

How should neffy® be stored and used?

neffy® should be stored at room temperature and always carried in pairs to ensure immediate access during an allergic emergency.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 28

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 161

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 342

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 24

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Mercy Medical Center Nurses Mobilize for Patient Safety Picket

Updated Category News Views 35

Nurses Standing Together for Patient Safety Nurses at Mercy Medical Center are uniting for a cause that affects them profoundly: the safety of their patients and the workplace. With issues surrounding unsafe staffing and deteriorating care conditions, nurses represented by the Massachusetts Nurses Association plan to hold an informational picket. This demonstration is not...

Continue Reading
Massive Merger: Qorvo and Skyworks Unite for Future Innovations

Updated Category News Views 306

Overview of the Strategic Merger In an exciting development in the technology sector, shares of Qorvo, Inc. (NASDAQ: QRVO) and Skyworks Solutions, Inc. (NASDAQ: SWKS) are experiencing a notable surge after announcing their intent to merge. This deal, which values the combined entity at approximately $22 billion, marks a significant step forward in the realm of...

Continue Reading
Oryzon Genomics Announces Corporate Updates for September

Updated Category News Views 178

Oryzon Genomics to Share Updates on Corporate Progress Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a leading clinical-stage biopharmaceutical company dedicated to epigenetic therapies for critical medical needs, is set to present its latest corporate updates at several major international events. These important gatherings scheduled for September will showcase...

Continue Reading
Envision Energy Launches Innovative Energy Storage Solution

Updated Category News Views 363

Introducing the EN 8 Pro: A Revolution in Energy Storage Envision Energy, a leader in sustainable technology, has made a significant breakthrough in energy management with the launch of its EN 8 Pro 8MWh DC Liquid-Cooled Energy Storage System. This innovative setup is set to establish new industry standards in safety, efficiency, and environmental adaptability. Designed...

Continue Reading
Beard Papa's Teams Up for Exciting Zenless Zone Zero Launch

Updated Category News Views 528

Beard Papa's Exciting Flavor Collaboration Begins Beard Papa's, renowned for its delectable cream puffs and irresistible custard fillings, is thrilled to announce a nationwide collaboration with Zenless Zone Zero. This partnership will launch an exciting in-game event that will allow fans to experience the unique flavors inspired by the action-RPG sensation from...

Continue Reading